Importantly, it remains the key therapeutic target for PCa, even in advanced, treatment-resistant disease7, where genomic alterations such as AR gene and regulatory element amplification, overexpression, mutations, and splice variants of AR drive continued reliance on androgen signaling8. This evidence concerns the gene AR and posterior cortical atrophy.